TRIP4抗体

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane: A431 cells, Primary antibody: P08030(TRIP4 Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08030(TRIP4 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P08030(TRIP4 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The thyroid hormone receptor interactor 4 (TRIP4), also known as ASC-1 or ACTR/AIB1 coactivator, is a protein involved in transcriptional regulation and RNA processing. It belongs to the ASCH-YJOD domain superfamily and functions as a transcriptional coactivator for nuclear receptors, including steroid hormone receptors, and other transcription factors like AP-1 and NF-κB. TRIP4 interacts with RNA polymerase II and components of the mediator complex, playing roles in cell proliferation, differentiation, and stress responses. Its structure includes an N-terminal cysteine-rich domain and a C-terminal activation domain, facilitating protein-protein interactions.

TRIP4 antibodies are essential tools for studying its expression, localization, and molecular interactions. Research links TRIP4 dysregulation to diseases, particularly cancer. Overexpression of TRIP4 is observed in lung, breast, and prostate cancers, correlating with tumor progression and poor prognosis. Antibodies against TRIP4 enable detection via techniques like Western blotting, immunohistochemistry, and immunoprecipitation, aiding in mechanistic studies of its oncogenic roles. Additionally, TRIP4 mutations are associated with developmental disorders, such as spinal muscular atrophy with congenital bone fractures, highlighting its importance in neuromuscular health.

Recent studies also explore TRIP4’s involvement in RNA splicing and DNA damage repair pathways. Validated TRIP4 antibodies help identify post-translational modifications and tissue-specific isoforms. However, antibody specificity remains a challenge, requiring careful validation using knockout controls. Continued research with TRIP4-targeting antibodies may uncover therapeutic strategies for cancers or genetic disorders linked to its dysfunction.